Various aspects of the disclosure relate to an intraocular pressure sensor.
Glaucoma is a leading cause of blindness, affecting an estimated four million Americans and seventy million individuals globally. As glaucoma typically affects the elderly, the aging demographic trends indicate that this disease will continue to be an ever-increasing socioeconomic burden to society. Elevated intraocular pressure (“IOP”) is a major risk factor for glaucoma, and IOP monitoring is the single most important clinical management tool. Today, an estimated 8-10% of Americans and 5-6% of people in other developed nations depend on implantable medical devices to support or rebuild organs and other functions of the body during their lifetime. Consequently, there is an urgent need to develop medical implant technologies that are biocompatible (e.g., anti-biofouling or biofouling-resistant) while maintaining high performance and reliability.
Disclosed are embodiments of IOP sensors and methods for fabrication of the same. In some embodiments, the IOP sensor can include: a first substrate having a recess on a first surface; and a second substrate disposed on the first surface of the first substrate such that the recess of the first surface and the second substrate form a cavity. The second substrate has a plurality of structures on a surface that opposes the cavity.
The plurality of structures can have an aspect ratio between 0.15 to 0.90. In some embodiments, the plurality of structures has an aspect ratio of approximately 0.45. The plurality of structures can have varying sizes and shapes. The plurality of structures can be a plurality of nanostructures that have an average inter-structural period can have a range between 300-500 nanometers. In some embodiments, the average inter-structural period is 100-200 nanometers. The plurality of structures can have a circular or oval shape.
The first substrate of the IOP sensor can be made of silicon (Si). The second substrate of the IOP sensor can be made of silicon nitride (Si3N4). The IOP sensor can further include a third substrate disposed on a portion of the second surface of the second substrate; and a fourth substrate disposed on the third substrate. The third substrate can be made of silicon dioxide (SiO2) and the first and fourth substrates can be made of silicon (Si).
The cavity of the IOP sensor can further include two or more trenches that are perpendicular to a length of the cavity. The trenches are located on a surface of the cavity that opposes the second substrate.
Also disclosed is a method for fabricating an intraocular pressure sensor. The method can include: spin-coating a first substrate assembly with a solution of polymers; evaporating a portion of the solution of polymers to form a plurality of islands on the first substrate assembly; removing the plurality of islands to form a first mask on the first substrate assembly, the first mask having a plurality of openings after removal of the islands; depositing a layer of metal-oxide on the first mask; removing the layer of metal-oxide to form a plurality of structures have an average aspect ratio of approximately 0.45 on the first substrate; and placing the first substrate assembly on a second substrate having a slot to form an optical cavity. The plurality of structures of the first substrate is placed over the slot of the second substrate.
The solution of polymers can include a first and a second polymer. The first polymer can be hydrophobic, and the second polymer can be hydrophilic or less hydrophobic. In some embodiment, the solution of polymers can be a solvent of methyl ethyl ketone with a solvent mass ratio of 35%. The first polymer can be polystyrene, and the second polymer can be poly-methyl-methacrylate.
Spin-coating the first substrate assembly can include: accelerating a spin of the first substrate from rest to 3500 rotation per minute (RPM) in 1.5 seconds; and spinning the first substrate assembly at 3500 RPM for 30 seconds. While spin-coating the first substrate assembly, the coating chamber can be maintained at a relative humidity between 40 to 50 percent.
Removing the islands from the first substrate can include: rinsing the first substrate assembly in cyclohexane between 1 to 3 minutes; and drying the first substrate assembly in a stream of nitrogen. Next, a layer of metal-oxide is deposited on the first mask. The layer of metal-oxide can be a 30 nm thick layer of Al2O3. Finally, the first substrate assembly is hermetically sealed to the second substrate to create an IOP sensor.
The islands, openings, and structures can generally be of any desired size. In many embodiments described herein, the plurality of islands is a plurality of nano-islands, the plurality of openings are a plurality of nano-openings, and the plurality of structures is a plurality of nanostructures. Those of ordinary skill in the art understand the term “nano” to imply a broad range of sizes that, as a matter of convenience, are typically expressed on the nanometer scale. The embodiments described herein can be practiced with nano-islands, nano-openings, and nanostructures having a largest length or width dimension from 0.1 nanometers to 10,000 nanometers, or 1 nanometer to 1000 nanometers, to name a few. The embodiments described herein can be practiced at dimensions less than 0.1 nanometers and more than 10,000 nanometers as well. Other example embodiments are provided herein.
Also disclosed is a second method for fabricating an intraocular pressure sensor. The second method can include: providing a first substrate layer having a plurality of structures; and disposing the first substrate layer on a second substrate having a slot to form an optical cavity. The plurality of structures can have an inter-structural period of 450 nm and an aspect ratio of 0.45. In the final IOP assembly, the plurality of structures of the first substrate layer is placed directly over the slot to form an optical cavity.
The features and advantages described in the specification are not all inclusive and, in particular, many additional features and advantages will be apparent to one of ordinary skill in the art in view of the drawings, specification, and claims. Moreover, it should be noted that the language used in the specification has been principally selected for readability and instructional purposes, and may not have been selected to delineate or circumscribe the disclosed subject matter.
The foregoing summary, as well as the following detailed description, is better understood when read in conjunction with the accompanying drawings. The accompanying drawings, which are incorporated herein and form part of the specification, illustrate a plurality of embodiments and, together with the description, further serve to explain the principles involved and to enable a person skilled in the relevant art(s) to make and use the disclosed technologies.
The figures and the following description describe certain embodiments by way of illustration only. One skilled in the art will readily recognize from the following description that alternative embodiments of the structures and methods illustrated herein may be employed without departing from the principles described herein. Reference will now be made in detail to several embodiments, examples of which are illustrated in the accompanying figures. It is noted that wherever practicable similar or like reference numbers may be used in the figures to indicate similar or like functionality.
As previously noted, there is a need to develop medical implant technologies that are anti-biofouling or biofouling-resistant while maintaining high performance and reliability. Such multifunctional surfaces are often seen in nature, which boasts a plethora of nanostructures with a wide array of desirable properties. For example, recent work has revealed the multifunctionality of high-aspect-ratio biophotonic nanostructures found on the wings of insects such as glasswing butterflies, danger cicada, and dragonflies. These nanostructures are needle-like and vertically tapered. They exhibit remarkable multifunctionality including omnidirectional antireflection, self-cleaning, antifouling, and bactericidal properties. Such properties may prove to be useful for engineering biofouling-resistant optical medical devices. In nature, these nanostructures are postulated to be self-assembled through a phase separation of biopolymers in the amphiphilic phospholipid bilayer of wing-scale cells, followed by chitin deposition in the extracellular space.
The IOP sensor disclosed herein was inspired from multifunctional biophotonic nanostructures found on the transparent wings of the longtail glasswing butterfly (chorinea faunus), which can help advance the versatility of implantable IOP sensors. To develop the nanostructures for the IOP sensor, the surface and optical properties of the short-range-ordered nanostructures found on the wings of the longtail glasswing butterfly (hereinafter referred to as C. faunus) are characterized in detail. Research of the C. faunus' wings reveals that the C. faunus relies on relatively moderate-aspect-ratio chitin nanostructures to produce transparency that is a unique combination of anti-reflection and Mie scattering, which has not been observed in other transparent wings found in nature. By adopting nature's biopolymer-phase-separation process, a highly scalable biomimetic bottom-up nanofabrication method is developed to create low-aspect-ratio bioinspired nanostructures (BINS) on freestanding silicon-nitride (Si3N4) membranes. Unlike previous high-aspect-ratio nonstructures that focused on replicating optical antireflection and bactericidal properties, the IOP sensor with BINS (or BINS-IOP sensor) of the present disclosure has a pseudo-periodic arrangement and dimensions that control short-range scattering to enhance omnidirectional optical transmission and angle independence while also exhibiting anti-biofouling properties of high-aspect-ratio nanostructures, which typically rely on physical cell lysis. In some embodiments, the BINS-IOP sensor can have a low-aspect-ratio, which displays strong hydrophilicity to form an aqueous anti-adhesion barrier for proteins and cellular fouling without cell lysis. Empirical data collected on the low-aspect-ratio BINS-IOP sensor of the present disclosure show significant improvement in the sensor's optical readout angle, pressure-sensing performance, and biocompatibility during a one-month in vivo study.
Third substrate layer 115 can be made of silicon-nitride (Si3N4) or other thermodynamically stable and/or biocompatible compounds. Third substrate layer 115 includes a plurality of nanostructures 125 on one of the surfaces that opposes fourth substrate layer 120, which includes a cavity 130. Third substrate layer 115 can have a thickness range between 200-400 nm (nanometer). In some embodiments, third substrate layer 115 can have a thickness of 300 nm. Nanostructures 125 can have an average aspect ratio in a range of 0.15 to 0.90. In some embodiments, nanostructures 125 can have an average aspect ratio of 0.45 and can be made of the same material as third substrate layer 115. Alternatively, nanostructures 125 and third substrate layer 115 can be made of different materials. Nanostructures 125 can have a circular, oval (e.g., ellipsoidal), pyramidal, or cylindrical shape. In some embodiments, nanostructures 125 have an ellipsoidal shape. Nanostructures 125 can have an average inter-structural period (the center-to-center distance between two adjacent nanostructures) in a range of 300 to 500 nm. In some embodiments, nanostructures 125 can have an average inter-structural period of 100-200 nm.
Similar to first substrate layer 105, fourth substrate layer 120 can have a thickness range between 200-400 nm (nanometer). In some embodiments, fourth substrate layer 120 can have a thickness of 300 nm.
Cavity 130 of fourth substrate layer 120 can also include one or more trenches 135 that are orthogonal to the length of cavity 130. In some embodiments, cavity 130 can have four trenches 135, which can function as reservoirs to wick and store any leftover (and unwanted) liquid that may be in cavity 130. For example, during a process to hermetically seal cavity 130 and third substrate layer 115, trenches 135 can collect and store any sealant or epoxy that may have overflow or leak into cavity 130. In some embodiments, cavity 130 can have a depth in a range of 3-10 μm. In one embodiment, cavity 130 can have a depth of 4 μm.
IOP sensor 100 can also include a sealing layer 140 that hermetically seals substrate layers 105, 110, 115, and 120 together to form a Fabry-Perot cavity. Sealing layer 140 can be made of a medical grade epoxy or other types of sealant materials. Sealing layer 140 can encompasses the entire circumference of substrate layers 105 and 120.
In
In
To form substrate assembly 530, a nanostructures-forming process 600 is performed. Referring to
In some embodiments, for the spin-coating process, substrate assembly 525 (without substrate layers 110 and 515, hereinafter referred to as substrate assembly 525′) is accelerated at a rate of 2000 rpm/s for 1.5 seconds to reach 3500 rpm. Substrate assembly 525′ is then spin-coated with the solution of polymers while being rotated at 3500 rpm for 30 seconds. The relative humidity of the spin-coating process can be maintained between 40% and 50%. Due to the difference in relative solubilities of the PS and the PMMA in the MEK solution, de-mixing (e.g., separation) of the blended polymers occurs in the coating layer while substrate 525′ is being spin-coated.
Referring now to
In
Empirical studies of the nanostructures of IOP sensor 100 show that the variation in average inter-structural periods plays an important role in the extent of light scattering. To confirm the scattering properties of IOP sensor 100, finite-difference time-domain (FDTD) simulations were performed on nanostructures with periods of 150 and 300 nm at 420-nm wavelength (
The optical properties of IOP sensor 100 was characterized using an angle resolved transmission spectroscopy in the visible near infrared (VIS-NIR) range. The results are then compared with the results of a conventional (flat) IOP sensor without the Si3N4 nanostructures. The conventional IOP sensor produced a transmission peak around 705 nm due to thin-film interference and its peak location blue-shifted 30 nm at 40° incident angle (see
The integration of nanostructures on an IOP sensor (e.g., IOP sensor 100) broadens the transmission-peak profile and moves its center to 715 nm, but most noticeably it limits the magnitude of peak shift to 15 nm at 40°, indicating a significant reduction in angle dependence (see
In vitro adhesion tests of representative proteins, prokaryotes, and eukaryotes were performed on IOP sensor 100 and conventional IOP sensor (e.g., sensor without nanostructures or flat IOP sensor) with lysine-coated glass slides as positive controls. Experimental results show that conventional IOP sensor is moderately hydrophilic, which has a contact angle between 35-40° (the angle between a droplet's edge and the surface). Moderate hydrophilic surfaces are known to promote cell adhesion and proliferation due to increased adsorption of proteins as compared to high hydrophilic surfaces, which have a contact angle of less than 20°. The nanostructures of IOP sensor 100 is highly hydrophilic, which is achieved by adjusting the surface roughness and by varying the aspect-ratios of the nanostructures from 0.15 to 0.90. Empirical data shows that an aspect ratio of 0.45 provides an optimum balance of high hydrophilicity and anti-adhesion properties. Accordingly, in some embodiments, nanostructures of IOP sensor 100 have an aspect ratio of approximately 0.45. Due to IOP sensor 100 strong hydrophilicity (contact angle less than) 20°, an aqueous barrier forms on the surface and limits protein adsorption and cell adhesion to provide an overall anti-adhesion character to IOP sensor 100.
Surface adhesion tests of two representative proteins and bacteria were performed on a control IOP sensor, a flat IOP sensor, and IOP sensor 100. The representative proteins were: (1) fluorescent-labelled bovine serum albumin (BSA) for its cardinal role in blood-material interactions and high non-specific binding affinity to the surfaces of biomaterials; and (2) streptavidin for its specific binding affinity to Si3N4 surfaces. The bacteria used in the adhesion test were E. coli.
Further adhesion tests were performed using the HeLa cell line, which is a representative eukaryote having exceptional robustness, aggressive growth rate, and adherent nature. After 72 hours, the adherent cell density on the conventional IOP sensor was eight times greater than that on IOP sensor 100 (see
Mortality ratio tests were also performed on a control IOP sensor, conventional IOP sensor, and IOP sensor 100. The number of dead cells to the number of living cells, was computed for each surface of the sensors every 24 hours over a 72-hour period. The difference in the mortality ratios of the two surfaces after 72 hours was not statistically significant (
These results highlight the advantage of the anti-biofouling approach based on strong hydrophilicity and anti-adhesion properties. High or moderate aspect-ratio nanostructures either with tapered sharp tips or dome-shaped tips as implemented in IOP sensor 100 display potent geometry-dependent bactericidal properties that induce large stresses and deformation on cell walls regardless of their surface chemical composition and actively promote autogenous lysis when placed in contact with mammalian cells. Such anti-biofouling approach relying on physical lysis could undesirably damage tissues surrounding implants and elicit inflammation.
Conventional sensors with a flat-surfaced membrane have successfully provided in vivo IOP measurements, but its accuracy and usability suffered from narrow readout angles inherent to conventional FP-resonators (
In contrast, the SNR of IOP sensor 100 remain relatively high at normal and at a wide range of angles (see
Finally, when tested in a pressure-controlled chamber interfaced with a digital pressure gauge, IOP sensor 100 showed excellent linearity (correlation factor: ˜1.00) over the clinically interested range from 0 to 30 mmHg (
Both IOP sensors 100 and conventional sensors were implanted individually inside the anterior chambers of two New Zealand white rabbits to investigate in vivo optical performance and biocompatibility. One hundred spectra with highest signal-to-noise ratio (SNR) were averaged in 1 minute of continual measurement to produce a single IOP readout. To examine the stability of sensor measurements, the shift Δλ of the most prominent peak in each spectrum of the set was then computed with respect to the mean (
Both sensors were retrieved after one month of implantation to quantify the surface cell growth and to assess biocompatibility. Confocal fluorescence microscopy was used to determine the extent of tissue growth and cellular viability at the time of retrieval. DAPI was used to localize all constituent cells while phalloidin, which selectively binds to actin, was used as an indicator of cellular processes and health. Additionally, matrix metalloproteinases-2 (MMP-2) was used as an indicator of inflammation for its role in various inflammatory and repair processes.
Z-stacked multi-channel immunofluorescence images of the conventional IOP sensor and IOP sensor 100 were generated (not shown). Based on the data collected from these images, 59% of the conventional was covered by tissue, and there was a healthy tissue growth at the time of extraction. Additionally, MMP-2 was observed over the membrane of the conventional sensor, which could have triggered the extensive cell migration towards this region.
In comparison, approximately 5% of the surface of IOP sensor 100 was covered by tissue, which was a 12-fold improvement over the conventional sensor, and there was no detectable MMP-2 signal. This suggests that the cell signaling and migration patterns present on the flat-surfaced (e.g., conventional) sensor were absent on the BINS-integrated sensor (e.g., IOP sensors 100, 200, 300, and 400). This also indicates no inflammation occurred post-implantation and highlights the promising role of the BINS towards significantly improving in vivo biocompatibility of medical implants.
The foregoing description of the embodiments has been presented for the purposes of illustration and description. It is not intended to be exhaustive or to limit the inventive subject matter to the precise form disclosed. Many modifications and variations are possible in light of the above teaching. It is intended that the scope of the present inventive subject matter be limited not by this detailed description, but rather by the claims of this application. As will be understood by those familiar with the art, the present inventive subject matter may be embodied in other specific forms without departing from the spirit or essential characteristics thereof.
Where a discrete value or range of values is set forth, it is noted that that value or range of values may be claimed more broadly than as a discrete number or range of numbers, unless indicated otherwise. For example, each value or range of values provided herein may be claimed as an approximation and this paragraph serves as antecedent basis and written support for the introduction of claims, at any time, that recite each such value or range of values as “approximately” that value, “approximately” that range of values, “about” that value, and/or “about” that range of values. Conversely, if a value or range of values is stated as an approximation or generalization, e.g., approximately X or about X, then that value or range of values can be claimed discretely without using such a broadening term. Those of skill in the art will readily understand the scope of those terms of approximation. Alternatively, each value set forth herein may be claimed as that value plus or minus 5%, and each lower limit of a range of values provided herein may be claimed as the lower limit of that range minus 5%, and each upper limit of a range of values provided herein may be claimed as the upper limit of that range plus 5%, and this paragraph serves as antecedent basis and written support for the introduction of claims, at any time, that recite those percentile variations.
Reference in the specification to “one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the inventive subject matter. The appearances of the phrase “in one embodiment” in various places in the specification are not necessarily all referring to the same embodiment.
In many instances entities are described herein as being coupled to other entities. It should be understood that the terms “coupled” and “connected” (or any of their forms) are used interchangeably herein and, in both cases, are generic to the direct coupling of two entities (without any non-negligible intervening entities) and the indirect coupling of two entities (with one or more non-negligible intervening entities). Where entities are shown as being directly coupled together, or described as coupled together without description of any intervening entity, it should be understood that those entities can be indirectly coupled together as well unless the context clearly dictates otherwise.
Additionally, as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.
This application claims priority to and benefit of U.S. Provisional Application No. 62/554,648 entitled “Longtail Glasswing Butterfly Inspired Biofouling-resistant Biophotonic Nanostructures for Implants”, filed Sep. 6, 2017, the disclosure of which is incorporated herein by reference in its entirety for all purposes.
This invention was made with government support under Grant No. EY024582 awarded by the National Institutes of Health. The government has certain rights in the invention.
Number | Date | Country | |
---|---|---|---|
62554648 | Sep 2017 | US |